Last reviewed · How we verify
High grade squamous intraepithelial neoplasia of esophagus — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Yervoy | Yervoy | Bristol-Myers Squibb | Cytotoxic T-lymphocyte protein 4 | |||
| Yervoy | ipilimumab | Bristol-Myers Squibb | CTLA-4-directed Blocking Antibody | Cytotoxic T-lymphocyte protein 4 | 2011-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 2 drugs in High grade squamous intraepithelial neoplasia of esophagus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in High grade squamous intraepithelial neoplasia of esophagus:
- High grade squamous intraepithelial neoplasia of esophagus treatment updates — RSS
- High grade squamous intraepithelial neoplasia of esophagus treatment updates — Atom
- High grade squamous intraepithelial neoplasia of esophagus treatment updates — JSON
Cite this brief
Drug Landscape (2026). High grade squamous intraepithelial neoplasia of esophagus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/high-grade-squamous-intraepithelial-neoplasia-of-esophagus. Accessed 2026-06-10.
Related
- High grade squamous intraepithelial neoplasia of esophagus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing